These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 21225912)

  • 41. Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.
    Li L; Sajdyk T; Smith EML; Chang CW; Li C; Ho RH; Hutchinson R; Wells E; Skiles JL; Winick N; Martin PL; Renbarger JL
    Clin Pharmacol Ther; 2019 Jun; 105(6):1421-1428. PubMed ID: 30506673
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.
    Guilhaumou R; Simon N; Quaranta S; Verschuur A; Lacarelle B; Andre N; Solas C
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1191-8. PubMed ID: 21404110
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Individualization of tacrolimus dosage basing on cytochrome P450 3A5 polymorphism--a prospective, randomized, controlled study.
    Chen SY; Li JL; Meng FH; Wang XD; Liu T; Li J; Liu LS; Fu Q; Huang M; Wang CX
    Clin Transplant; 2013; 27(3):E272-81. PubMed ID: 23432535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. CYP3A5 genotype affects time to therapeutic tacrolimus level in pediatric kidney transplant recipients.
    Yanik MV; Seifert ME; Locke JE; Hauptfeld-Dolejsek V; Crowley MR; Cutter GR; Mannon RB; Feig DI; Limdi NA
    Pediatr Transplant; 2019 Aug; 23(5):e13494. PubMed ID: 31124575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of CYP3A5 genetic polymorphisms on adverse events in patients with ulcerative colitis treated with tacrolimus.
    Asada A; Bamba S; Morita Y; Takahashi K; Imaeda H; Nishida A; Inatomi O; Sugimoto M; Sasaki M; Andoh A
    Dig Liver Dis; 2017 Jan; 49(1):24-28. PubMed ID: 27717793
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effects of cytochrome P450 family 3 subfamily A member 5 gene polymorphisms on daunorubicin metabolism and adverse reactions in patients with acute leukemia.
    Huang Z; Wang J; Qian J; Li Y; Xu Z; Chen M; Tong H
    Mol Med Rep; 2017 Jun; 15(6):3493-3498. PubMed ID: 28440407
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Population pharmacokinetics and pharmacogenetics of apatinib in adult cancer patients.
    Yang XM; Ye PP; Liu XL; Guo ZX; Kan M; Li Q; Song LL; Liu HY; Chen KG; Shi JY; Zhang YH; Li Y; Zhao FR; van den Anker J; Li Y; Zhao W
    Br J Clin Pharmacol; 2023 Jun; 89(6):1862-1872. PubMed ID: 36662574
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacogenomics of Vincristine-Induced Peripheral Neuropathy Implicates Pharmacokinetic and Inherited Neuropathy Genes.
    Wright GEB; Amstutz U; Drögemöller BI; Shih J; Rassekh SR; Hayden MR; Carleton BC; Ross CJD;
    Clin Pharmacol Ther; 2019 Feb; 105(2):402-410. PubMed ID: 29999516
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nifedipine pharmacokinetics are influenced by CYP3A5 genotype when used as a preterm labor tocolytic.
    Haas DM; Quinney SK; Clay JM; Renbarger JL; Hebert MF; Clark S; Umans JG; Caritis SN;
    Am J Perinatol; 2013 Apr; 30(4):275-81. PubMed ID: 22875663
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vincristine-induced peripheral neuropathy: A mini-review.
    Li GZ; Hu YH; Li DY; Zhang Y; Guo HL; Li YM; Chen F; Xu J
    Neurotoxicology; 2020 Dec; 81():161-171. PubMed ID: 33053366
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Variants in vincristine pharmacodynamic genes involved in neurotoxicity at induction phase in the therapy of pediatric acute lymphoblastic leukemia.
    Martin-Guerrero I; Gutierrez-Camino A; Echebarria-Barona A; Astigarraga I; Garcia de Andoin N; Navajas A; Garcia-Orad A
    Pharmacogenomics J; 2019 Dec; 19(6):564-569. PubMed ID: 30723315
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
    Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
    Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dynamic effects of CYP3A5 polymorphism on dose requirement and trough concentration of tacrolimus in renal transplant recipients.
    Chen P; Li J; Li J; Deng R; Fu Q; Chen J; Huang M; Chen X; Wang C
    J Clin Pharm Ther; 2017 Feb; 42(1):93-97. PubMed ID: 27885697
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CYP3A5 genotype is not associated with a higher risk of acute rejection in tacrolimus-treated renal transplant recipients.
    Hesselink DA; van Schaik RH; van Agteren M; de Fijter JW; Hartmann A; Zeier M; Budde K; Kuypers DR; Pisarski P; Le Meur Y; Mamelok RD; van Gelder T
    Pharmacogenet Genomics; 2008 Apr; 18(4):339-48. PubMed ID: 18334918
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Selective metabolism of vincristine in vitro by CYP3A5.
    Dennison JB; Kulanthaivel P; Barbuch RJ; Renbarger JL; Ehlhardt WJ; Hall SD
    Drug Metab Dispos; 2006 Aug; 34(8):1317-27. PubMed ID: 16679390
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention.
    Park KW; Kang J; Park JJ; Yang HM; Lee HY; Kang HJ; Koo BK; Oh BH; Park YB; Kim HS
    Heart; 2012 Sep; 98(18):1366-72. PubMed ID: 22735685
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP3A4*22 and CYP3A5*3 are associated with increased levels of plasma simvastatin concentrations in the cholesterol and pharmacogenetics study cohort.
    Kitzmiller JP; Luzum JA; Baldassarre D; Krauss RM; Medina MW
    Pharmacogenet Genomics; 2014 Oct; 24(10):486-91. PubMed ID: 25051018
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of CYP3A5 and ABCB1 gene polymorphisms on calcineurin inhibitor-related neurotoxicity after hematopoietic stem cell transplantation.
    Yanagimachi M; Naruto T; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto H; Yagihashi T; Kosaki K; Yokota S
    Clin Transplant; 2010; 24(6):855-61. PubMed ID: 20030680
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multidrug resistance-associated protein 2 (MRP2/ABCC2) haplotypes significantly affect the pharmacokinetics of tacrolimus in kidney transplant recipients.
    Ogasawara K; Chitnis SD; Gohh RY; Christians U; Akhlaghi F
    Clin Pharmacokinet; 2013 Sep; 52(9):751-62. PubMed ID: 23633119
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vincristine-induced neuropathy in childhood ALL (acute lymphoblastic leukemia) survivors: prevalence and electrophysiological characteristics.
    Jain P; Gulati S; Seth R; Bakhshi S; Toteja GS; Pandey RM
    J Child Neurol; 2014 Jul; 29(7):932-7. PubMed ID: 23781018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.